Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair

Robin I. Dewalt, Kenneth A. Kesler, Zane T. Hammoud, Lee Ann Baldridge, Eyas M. Hattab, Shadia I. Jalal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Esophageal adenocarcinoma (EAC) continues to be a disease associated with high mortality. Among the factors leading to poor outcomes are innate resistance to currently available therapies, advanced stage at diagnosis, and complex biology. Platinum and ionizing radiation form the backbone of treatment for the majority of patients with EAC. Of the multiple processes involved in response to platinum chemotherapy or ionizing radiation, deoxyribonucleic acid (DNA) repair has been a major player in cancer sensitivity to these agents. DNA repair defects have been described in various malignancies. The purpose of this study was to determine whether alterations in DNA repair are present in EAC compared with normal gastroesophageal tissues. Methods: We analyzed the expression of genes involved in homologous recombination (HR), nonhomologous end-joining, and nucleotide excision repair (NER) pathways in 12 EAC tumor samples with their matched normal counterparts. These pathways were chosen because they are the main pathways involved in the repair of platinum- or ionizing-radiation-induced damage. In addition, abnormalities in these pathways have not been well characterized in EAC. Results: We identified increased expression of at least one HR gene in eight of the EAC tumor samples. Alterations in the expression of EME1, a structure-specific endonuclease involved in HR, were the most prevalent, with messenger (m)RNA overexpression in six of the EAC samples. In addition, all EAC samples revealed decreased expression of at least one of numerous NER genes including XPC, XPA, DDB2, XPF, and XPG. Conclusion: Our study identified DNA repair dysregulation in EAC involving two critical pathways, HR and NER, and is the first demonstration of EME1 upregulation in any cancer. These DNA repair abnormalities have the potential to affect a number of processes such as genomic instability and therapy response, and the consequences of these defects deserve further study in EAC.

Original languageEnglish (US)
Pages (from-to)11-20
Number of pages10
JournalLung Cancer: Targets and Therapy
Volume5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Esophagogastric Junction
Homologous Recombination
DNA Repair
Adenocarcinoma
Ionizing Radiation
Platinum
DNA
Neoplasms
Critical Pathways
Genomic Instability
Endonucleases
Genes
Up-Regulation
Therapeutics
Gene Expression
Drug Therapy

Keywords

  • DNA repair
  • Esophageal adenocarcinoma
  • MUS81/EME1

ASJC Scopus subject areas

  • Oncology

Cite this

Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair. / Dewalt, Robin I.; Kesler, Kenneth A.; Hammoud, Zane T.; Baldridge, Lee Ann; Hattab, Eyas M.; Jalal, Shadia I.

In: Lung Cancer: Targets and Therapy, Vol. 5, 01.01.2014, p. 11-20.

Research output: Contribution to journalArticle

@article{c84a82f49cc04541a1a95cac4b49c903,
title = "Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair",
abstract = "Objective: Esophageal adenocarcinoma (EAC) continues to be a disease associated with high mortality. Among the factors leading to poor outcomes are innate resistance to currently available therapies, advanced stage at diagnosis, and complex biology. Platinum and ionizing radiation form the backbone of treatment for the majority of patients with EAC. Of the multiple processes involved in response to platinum chemotherapy or ionizing radiation, deoxyribonucleic acid (DNA) repair has been a major player in cancer sensitivity to these agents. DNA repair defects have been described in various malignancies. The purpose of this study was to determine whether alterations in DNA repair are present in EAC compared with normal gastroesophageal tissues. Methods: We analyzed the expression of genes involved in homologous recombination (HR), nonhomologous end-joining, and nucleotide excision repair (NER) pathways in 12 EAC tumor samples with their matched normal counterparts. These pathways were chosen because they are the main pathways involved in the repair of platinum- or ionizing-radiation-induced damage. In addition, abnormalities in these pathways have not been well characterized in EAC. Results: We identified increased expression of at least one HR gene in eight of the EAC tumor samples. Alterations in the expression of EME1, a structure-specific endonuclease involved in HR, were the most prevalent, with messenger (m)RNA overexpression in six of the EAC samples. In addition, all EAC samples revealed decreased expression of at least one of numerous NER genes including XPC, XPA, DDB2, XPF, and XPG. Conclusion: Our study identified DNA repair dysregulation in EAC involving two critical pathways, HR and NER, and is the first demonstration of EME1 upregulation in any cancer. These DNA repair abnormalities have the potential to affect a number of processes such as genomic instability and therapy response, and the consequences of these defects deserve further study in EAC.",
keywords = "DNA repair, Esophageal adenocarcinoma, MUS81/EME1",
author = "Dewalt, {Robin I.} and Kesler, {Kenneth A.} and Hammoud, {Zane T.} and Baldridge, {Lee Ann} and Hattab, {Eyas M.} and Jalal, {Shadia I.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2147/LCTT.S57594",
language = "English (US)",
volume = "5",
pages = "11--20",
journal = "Lung Cancer: Targets and Therapy",
issn = "1179-2728",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair

AU - Dewalt, Robin I.

AU - Kesler, Kenneth A.

AU - Hammoud, Zane T.

AU - Baldridge, Lee Ann

AU - Hattab, Eyas M.

AU - Jalal, Shadia I.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: Esophageal adenocarcinoma (EAC) continues to be a disease associated with high mortality. Among the factors leading to poor outcomes are innate resistance to currently available therapies, advanced stage at diagnosis, and complex biology. Platinum and ionizing radiation form the backbone of treatment for the majority of patients with EAC. Of the multiple processes involved in response to platinum chemotherapy or ionizing radiation, deoxyribonucleic acid (DNA) repair has been a major player in cancer sensitivity to these agents. DNA repair defects have been described in various malignancies. The purpose of this study was to determine whether alterations in DNA repair are present in EAC compared with normal gastroesophageal tissues. Methods: We analyzed the expression of genes involved in homologous recombination (HR), nonhomologous end-joining, and nucleotide excision repair (NER) pathways in 12 EAC tumor samples with their matched normal counterparts. These pathways were chosen because they are the main pathways involved in the repair of platinum- or ionizing-radiation-induced damage. In addition, abnormalities in these pathways have not been well characterized in EAC. Results: We identified increased expression of at least one HR gene in eight of the EAC tumor samples. Alterations in the expression of EME1, a structure-specific endonuclease involved in HR, were the most prevalent, with messenger (m)RNA overexpression in six of the EAC samples. In addition, all EAC samples revealed decreased expression of at least one of numerous NER genes including XPC, XPA, DDB2, XPF, and XPG. Conclusion: Our study identified DNA repair dysregulation in EAC involving two critical pathways, HR and NER, and is the first demonstration of EME1 upregulation in any cancer. These DNA repair abnormalities have the potential to affect a number of processes such as genomic instability and therapy response, and the consequences of these defects deserve further study in EAC.

AB - Objective: Esophageal adenocarcinoma (EAC) continues to be a disease associated with high mortality. Among the factors leading to poor outcomes are innate resistance to currently available therapies, advanced stage at diagnosis, and complex biology. Platinum and ionizing radiation form the backbone of treatment for the majority of patients with EAC. Of the multiple processes involved in response to platinum chemotherapy or ionizing radiation, deoxyribonucleic acid (DNA) repair has been a major player in cancer sensitivity to these agents. DNA repair defects have been described in various malignancies. The purpose of this study was to determine whether alterations in DNA repair are present in EAC compared with normal gastroesophageal tissues. Methods: We analyzed the expression of genes involved in homologous recombination (HR), nonhomologous end-joining, and nucleotide excision repair (NER) pathways in 12 EAC tumor samples with their matched normal counterparts. These pathways were chosen because they are the main pathways involved in the repair of platinum- or ionizing-radiation-induced damage. In addition, abnormalities in these pathways have not been well characterized in EAC. Results: We identified increased expression of at least one HR gene in eight of the EAC tumor samples. Alterations in the expression of EME1, a structure-specific endonuclease involved in HR, were the most prevalent, with messenger (m)RNA overexpression in six of the EAC samples. In addition, all EAC samples revealed decreased expression of at least one of numerous NER genes including XPC, XPA, DDB2, XPF, and XPG. Conclusion: Our study identified DNA repair dysregulation in EAC involving two critical pathways, HR and NER, and is the first demonstration of EME1 upregulation in any cancer. These DNA repair abnormalities have the potential to affect a number of processes such as genomic instability and therapy response, and the consequences of these defects deserve further study in EAC.

KW - DNA repair

KW - Esophageal adenocarcinoma

KW - MUS81/EME1

UR - http://www.scopus.com/inward/record.url?scp=84897016183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897016183&partnerID=8YFLogxK

U2 - 10.2147/LCTT.S57594

DO - 10.2147/LCTT.S57594

M3 - Article

AN - SCOPUS:84897016183

VL - 5

SP - 11

EP - 20

JO - Lung Cancer: Targets and Therapy

JF - Lung Cancer: Targets and Therapy

SN - 1179-2728

ER -